peripheral neuropathy is a well described complication in children with cancer. oncologists are generally well aware of the toxicity of the main agents, but fear the side effects of new drugs. as chemotherapeutic agents have been correlated with the activation of the immune system such as in chemotherapy Induced peripheral neuropathy (CIPN), an abnormal response can lead to autoimmune peripheral neuropathy (APN). although less frequent but more severe, radiation Induced peripheral neuropathy may be related to irreversible peripheral nervous system (PNS). pediatric cancer patients also have a higher risk of entering a pediatric Intensive care Unit for complications related to therapy and disease. Injury to peripheral nerves is cumulative, and frequently, the additional stress of a malignancy and its therapy can unmask a subclinical neuropathy. emerging risk factors for CIPN include treatment factors such as dose, duration and concurrent medication along with patient factors, namely age and inherited susceptibilities. the recent identification of individual genetic variations has advanced the understanding of physiopathological mechanisms and may direct future treatment approaches. more research is needed on pharmacological agents for the prevention or treatment of the condition as well as rehabilitation interventions, in order to allow for the simultaneous delivery of optimal cancer therapy and the mitigation of toxicity associated with pain and functional impairment. the aim of this paper is to review literature data regarding PNS complications in non-primary pediatric cancer.

Pro, S., Vinti, L., Boni, A., Mastronuzzi, A., Scilipoti, M., Velardi, M., et al. (2021). Peripheral Nervous System Involvement in Non-Primary Pediatric Cancer: From Neurotoxicity to Possible Etiologies. JOURNAL OF CLINICAL MEDICINE, 10(14) [10.3390/jcm10143016].

Peripheral Nervous System Involvement in Non-Primary Pediatric Cancer: From Neurotoxicity to Possible Etiologies

Valeriani, Massimiliano;
2021-07-06

Abstract

peripheral neuropathy is a well described complication in children with cancer. oncologists are generally well aware of the toxicity of the main agents, but fear the side effects of new drugs. as chemotherapeutic agents have been correlated with the activation of the immune system such as in chemotherapy Induced peripheral neuropathy (CIPN), an abnormal response can lead to autoimmune peripheral neuropathy (APN). although less frequent but more severe, radiation Induced peripheral neuropathy may be related to irreversible peripheral nervous system (PNS). pediatric cancer patients also have a higher risk of entering a pediatric Intensive care Unit for complications related to therapy and disease. Injury to peripheral nerves is cumulative, and frequently, the additional stress of a malignancy and its therapy can unmask a subclinical neuropathy. emerging risk factors for CIPN include treatment factors such as dose, duration and concurrent medication along with patient factors, namely age and inherited susceptibilities. the recent identification of individual genetic variations has advanced the understanding of physiopathological mechanisms and may direct future treatment approaches. more research is needed on pharmacological agents for the prevention or treatment of the condition as well as rehabilitation interventions, in order to allow for the simultaneous delivery of optimal cancer therapy and the mitigation of toxicity associated with pain and functional impairment. the aim of this paper is to review literature data regarding PNS complications in non-primary pediatric cancer.
6-lug-2021
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/39
English
complications
pediatric cancer
peripheral nervous system
peripheral neuropathy
Pro, S., Vinti, L., Boni, A., Mastronuzzi, A., Scilipoti, M., Velardi, M., et al. (2021). Peripheral Nervous System Involvement in Non-Primary Pediatric Cancer: From Neurotoxicity to Possible Etiologies. JOURNAL OF CLINICAL MEDICINE, 10(14) [10.3390/jcm10143016].
Pro, S; Vinti, L; Boni, A; Mastronuzzi, A; Scilipoti, M; Velardi, M; Caroleo, Am; Farina, E; Badolato, F; Alessi, I; Di Nardo, G; Carai, A; Valeriani, M; Reale, A; Parisi, P; Raucci, U
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
jcm-10-03016.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.81 MB
Formato Adobe PDF
1.81 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/363883
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact